Beijing Scitop Bio-Tech Co., Ltd. Class A

Beijing Scitop Bio-Tech Co., Ltd. Class A

SSZSE:300858
12.98
CNY
-0.35
(-2.63%)
0.21EPS
72.05P/E
3.98BMarket Cap
Apr 28Next Earn

Total Valuation

CNY

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A carries a market capitalization of 3.98B, placing it among publicly traded companies globally. Its enterprise value stands at 3.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.98B
Enterprise Value3.38B

Important Dates

Beijing Scitop Bio-Tech Co., Ltd. Class A's next confirmed earnings release is scheduled for April 28, 2027.

Earnings Date4/28/2027

Share Statistics

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A has 263.50M shares outstanding.

Shares Outstanding263.50M

Valuation Ratios

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 72.05. The price-to-sales ratio is 10.66, and the price-to-book ratio stands at 2.26.

PE Ratio72.05
PS Ratio10.66
PB Ratio2.26
P/TBV Ratio2.34

Enterprise Valuation

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A trades at an EV/EBITDA multiple of 61.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 61.86 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.38B versus a market cap of 3.98B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.26
EV / EBITDA61.86
EV / EBIT61.86

Financial Position

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A maintains a current ratio of 4.98, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.20, indicating conservative leverage, while an interest coverage ratio of 432.20 demonstrates strong ability to service its debt obligations.

Current Ratio4.98
Quick Ratio3.81
Debt / Equity0.20
Debt / EBITDA0.06
Interest Coverage432.20

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A posted a return on equity (ROE) of 3.04, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.76, measuring how efficiently the asset base is converted into earnings. The company generates approximately 884,216.89 in revenue per employee across its workforce of 413.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.67 indicates how many times Beijing Scitop Bio-Tech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)3.04
Return on Assets (ROA)2.76
Revenue Per Employee884,216.89
Employee Count413.00
Inventory Turnover3.67

Taxes

CNY

Over the twelve months ended September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A recorded an income tax benefit of -221,294.06 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 53.82M, leaving 54.04M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-221,294.06

Stock Price Statistics

CNY

As of the close on November 17, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A's stock has declined approximately 32.75% over the past 52 weeks. The 50-day moving average sits at 14.04, while the 200-day moving average is 16.09.

52-Week Price Change-32.75%
50-Day Moving Average14.04
200-Day Moving Average16.09

Income Statement

CNY

Over the twelve months ended September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A generated 365.18M in revenue and converted that into 54.04M in net income, yielding earnings per share of 0.21. EBITDA reached 54.65M, while operating income came in at 38.22M.

Revenue365.18M
Gross Profit167.64M
Operating Income38.22M
Pretax Income53.82M
Net Income54.04M
EBITDA54.65M
EBIT54.65M
Earnings Per Share (EPS)0.21

Balance Sheet

CNY

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A holds 607.33M in cash and equivalents against 3.54M in total debt, resulting in a net debt position of -155.42M. Total book value stands at 1.76B, with working capital of 635.20M providing operational flexibility.

Cash & Cash Equivalents607.33M
Total Debt3.54M
Net Debt-155.42M
Equity (Book Value)1.76B
Book Value Per Share6.69
Working Capital635.20M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-110.40M

Margins

Over the twelve months ended September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A posted a gross margin of 45.90, reflecting its pricing power and cost economics. The operating margin of 10.47 and net profit margin of 14.80 provide insight into operational efficiency.

Gross Margin45.90
Operating Margin10.47
Pretax Margin14.74
Profit Margin14.80
EBITDA Margin14.96

Dividends & Yields

Over the twelve months ended September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.96, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Beijing Scitop Bio-Tech Co., Ltd. Class A shareholders.

Shareholder Yield2.96

Stock Splits

Beijing Scitop Bio-Tech Co., Ltd. Class A's most recent stock split took place on June 30, 2023 with a 2:3 split ratio.

Last Split Date6/30/2023
Split Ratio2:3

Scores

As of September 30, 2026, Beijing Scitop Bio-Tech Co., Ltd. Class A has an Altman Z-Score of 12.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score12.25